button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1 certainty unassessable-11%- certainty unassessable-15%
ipilimumab alone vs. interferon alpha 1 low degree of certaintystatistically conclusive-16%- low degree of certainty-14%
versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 certainty unassessable-12%- certainty unassessablestatistically conclusive-32%
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -- certainty unassessable-55%
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1 certainty unassessablestatistically conclusive-26%- certainty unassessablestatistically conclusive-23%
nivolumab alone vs. placebo 1 -- certainty unassessablestatistically conclusive-40%
nivolumab plus ipilimumab vs. placebo 1 -- certainty unassessablestatistically conclusive-71%
pembrolizumab alone vs. placebo 1 -- certainty unassessablestatistically conclusive-40%

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

versus placebo
pembrolizumab alone vs. placebo 1 -- certainty unassessablestatistically conclusive-42%

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-34% certainty unassessablestatistically conclusive-40%-
nivolumab plus ipilimumab vs. ipilimumab alone 2 statistically conclusive-38%statistically conclusive-54%-
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 certainty unassessable-48%--
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 certainty unassessable-32% certainty unassessable-24%-
relatlimab plus nivolumab vs. nivolumab alone 1 - certainty unassessable-23%-
versus Standard of Care (SoC)
tremelimumab vs. Standard of Care (SoC) 1 certainty unassessable-11%--

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 certainty unassessable+44% certainty unassessable-57%-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-14% certainty unassessable-20%-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 certainty unassessablestatistically conclusive-53% certainty unassessablestatistically conclusive-52%-
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 - certainty unassessablestatistically conclusive-55%-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 certainty unassessable+6% certainty unassessable+15%-

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus gp100
ipilimumab alone vs. gp100 1 certainty unassessablestatistically conclusive-31%--
ipilimumab plus gp100 vs. gp100 1 certainty unassessablestatistically conclusive-29%--
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-15% certainty unassessable-10%-
ipilimumab plus gp100 vs. ipilimumab alone 1 certainty unassessable+4%--
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-39%-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-34% certainty unassessablestatistically conclusive-39%-
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-26% certainty unassessablestatistically conclusive-22%-
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 certainty unassessable-5% certainty unassessable+3%-
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable-24% certainty unassessablestatistically conclusive-46%-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable-13% certainty unassessablestatistically conclusive-40%-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-22% certainty unassessable-31%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons